Major cancer surgery on Jehovah's Witnesses;Større kirurgiske inngrep hos Jehovas vitner

Tidsskrift for den Norske Laegeforening

Volumn 126, Issue 20, 2006, Pages 2658-2661

  Høiseth, Lars Øivind ^a,c   Giercksky, Karl Erik ^b   Larsen, Stein Gunnar ^a   Kongsgaard, Ulf ^b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

BLOOD TRANSFUSION; CANCER SURGERY; CONTROLLED STUDY; EXPERIENTIAL LEARNING; HEMOGLOBIN BLOOD LEVEL; HUMAN; JEHOVAH'S WITNESS; MAJOR CLINICAL STUDY; MEDICAL ETHICS; MEDICAL LITERATURE; MEDICAL RECORD; MEDICOLEGAL ASPECT; PREOPERATIVE EVALUATION; REVIEW; SURGICAL TECHNIQUE; TREATMENT PLANNING; TREATMENT REFUSAL;

ADENOCARCINOMA; AGED; BLOOD TRANSFUSION; ERYTHROPOIETIN; FEMALE; HEMODILUTION; HUMANS; JEHOVAH'S WITNESSES; MALE; NEOPLASMS; PATIENT CARE PLANNING; RECTAL NEOPLASMS; RELIGION AND MEDICINE; RETROSPECTIVE STUDIES;

EID: 33750353860     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Jabbour N, Gagandeep S, Mateo R et al. Transfusion free surgery: single institution experience of 27 consecutive liver transplants in Jehovah's Witnesses. J Am Coll Surg 2005; 201: 412-7.
2. Dupuis JF, Nguyen DT. Anesthetic management of the patient who refuses blood transfusions. Int Anesthesiol Clin 1998; 36: 117-31.
3. Shander A, Rijhwani TS. Acute normovolemic hemodilution. Transfusion 2004; 44: 26-34.
4. Heier HE, Sørlie D, Søreide E et al. Transfusjon kontra alternative behandlingmetoder ved akutte blødninger. Rapport fra Kunnskapssenteret, nr. 8-2005. Oslo: Nasjonalt kunnskapssenter for helsetjenesten, 2005.
5. Weiskopf RB. Efficacy of acute normovolemic hemodilution assessed as a function of fraction of blood volume lost. Anesthesiology 2001; 94: 439-46.
6. Waters JH. Indications and contraindications of cell salvage. Transfusion 2004; 44: 40-4.
7. Waters JH, Tuohy MJ, Hobson DF et al. Bacterial reduction by cell salvage washing and leukocyte depletion filtration. Anesthesiology 2003; 99: 652-5.
8. Kongsgaard UE, Wang MY, Kvalheim G. Leucocyte depletion filter removes cancer cells in human blood. Acta Anaesthesiol Scand 1996; 40: 118-20.
9. Davis M, Sofer M, Gomez-Marin O et al. The use of cell salvage during radical retropubic prostatectomy: does it influence cancer recurrence? BJU Int 2003; 91: 474-6.
10. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997; 336: 933-8.
11. Monk TG. Preoperative recombinant human erythropoietin in anemic surgical patients. Crit Care 2004; 8 (suppl 2): 45-8.
12. Braga M, Gianotti L, Vignali A et al. Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. Br J Surg 1995; 82: 1637-40.
13. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96: 823-33.
14. Stasi R, Amadori S, Littlewood TJ et al. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. Oncologist 2005; 10: 539-54.
15. Sigmund H. Alternativer til blodtransfusion. Rapport fra det internationale ISPOT-projekt om teknologier til begrænsning af almindelig blodtransfusion ved planlagte operationer. Medicinsk Teknologivurdering 2001; 3: nr. 2. www.cemtv.dk/publikationer/docs/Ispot/ISPOT.pdf (25.8.2006).
16. Frilling A, Stavrou GA, Mischinger HJ et al. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg 2005; 390: 114-20.
17. Halvorsen M. Pasienter som nekter behandling. Tidsskr Nor Lægeforen 2002; 122: 323-4.
18. Syse A, Befring AK. Barn kan få blod uten foreldres samtykke. Tidsskr Nor Lægeforen 2003; 123: 2477.
19. http://www.watchtower.org/languages/norwegian/library/hb/index.htm (28.6.2006).
20. Carson JL, Duff A, Poses RM et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348: 1055-60.
21. Hebert PC, Yetisir E, Martin C et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001; 29: 227-34.
22. http://www.focustrial.org (28 6 2006).
23. van Woerkens EC, Trouwborst A, van Lanschot JJ. Profound hemodilution: what is the critical level of hemodilution at which oxygen delivery-dependent oxygen consumption starts in an anesthetized human? Anesth Analg 1992; 75: 818-21.
24. Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion 1994; 34: 396-401.